InVivo Therapeutics (NVIV) Announces Seventh Patient Conversion In The INSPIRE Study Of The Neuro-Spinal Scaffold

Publication Source: BioSpace.com

March 28, 2017

Patient Converts from Complete to Incomplete Spinal Cord Injury with Sensory and Motor Improvements

CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today announced that the patient enrolled in January in the INSPIRE study of the Neuro-Spinal Scaffold™ has improved from a complete AIS A spinal cord injury (SCI) to an incomplete AIS B SCI in the time between the one-month and the two-month evaluations. This is the seventh out of the 11 patients (63.6% conversion rate) with at least one month of follow-up to have had an AIS grade improvement. Two additional patients are early in follow-up and have not yet had their one-month visit. The AIS conversion rate observed in the INSPIRE study to date is considerably higher than published rates observed in a range of SCI natural history databases that are all below 25%.

“We are excited to announce the seventh AIS conversion in the INSPIRE study”
In addition to the AIS conversion, the patient has also experienced substantial improvements in sensory and motor function. Prior to surgery, the subject had a T12 neurological level of injury with some spared bilateral sensation on the front of the legs and unilateral palpable hip muscle contraction but no ability to move either leg. The patient had no sensory function on the front of the legs from just below the knee and no sensory function on the back of the body from just below the waist. At the two-month visit, the patient was able to move his hips and knees bilaterally and had regained at least some sensory function in almost all regions across the lower legs, feet, and the back of the body from just below the waist.

Travis Dumont, M.D., Director of the Neurovascular Program and Principal Investigator at Banner -University Medical Center Tucson, performed the implantation in January. Dr. Dumont said, “It has been rewarding to be a part of the INSPIRE study and to follow this patient’s recovery. This patient had a very low thoracic neurological level of injury, and such patients have the best prognosis. Nonetheless, I have been impressed with this patient’s recovery to date and am hopeful that the positive trajectory will continue.”

“We are excited to announce the seventh AIS conversion in the INSPIRE study,” CEO and Chairman Mark Perrin said. “We are equally pleased that this patient has experienced considerable motor and sensory improvement over the first two months following injury. We look forward to following the patient’s progress and hope for continued recovery.”

About the Neuro-Spinal Scaffold Implant

Following acute spinal cord injury, surgical implantation of the biodegradable Neuro-Spinal Scaffold within the decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity formation, sparing white matter, and allowing neural regeneration across the healed wound epicenter. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated in the INSPIRE pivotal probable benefit study for the treatment of patients with complete (AIS A) traumatic acute spinal cord injury.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws.  These statements can be identified by words such as “believe,” “anticipate,” “intend,” “estimate,” “will,” “may,” “should,” “expect,” “designed to,” “potentially,” and similar expressions, and include statements regarding the safety and effectiveness of the Neuro-Spinal Scaffold, progress toward achievement of OPC for The INSPIRE Study, the expected timing of full enrollment in the study, the ability of the company to open a site in Canada or enroll patients in Canada, and the timing of the submission of the Humanitarian Device Exemption (HDE). Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the company’s ability to successfully open additional clinical sites for enrollment and to enroll additional patients; the timing of the Institutional Review Board process; the impact of achieving the OPC on the FDA approval process; the company’s ability to commercialize its products; the company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the company’s products and technology in connection with the treatment of spinal cord injuries; the availability of substantial additional funding for the company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in the company’s Annual Report on Form 10-K for the year ended December 31, 2015, and its other filings with the SEC, including the company’s Form 10-Qs and current reports on Form 8-K. The company does not undertake to update these forward-looking statements.

Read More